

Special Issue

Development of Vaccines against Zika Virus

Message from the Guest Editors

Zika virus (ZIKV) is a neurotropic, mosquito-transmitted flavivirus, which recently, and alarmingly, has been demonstrated to be transmitted by sexual and transplacental routes. Of relevance is the transplacental route of infection because of its association with the development of microcephaly and other severe birth defects in babies born to ZIKV infected mothers. Currently, there are no approved vaccines or therapies to combat ZIKV infection. Immune-based therapies have historically been successful in controlling a number of viral infections. Therefore, development of new vaccines and therapies that can confer immunity and/or treat clinical symptoms of ZIKV is greatly desired. I hope that you will agree to share your expertise in this area by writing a review article for our Special Issue. The journal will follow up with instructions and other logistics for your review. Keywords: Zika virus; Flaviviruses; Vaccines; Animal models; Immune responses

Guest Editors

Prof. Kar Muthumani

1. Vaccine & Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA
2. GeneOne Life Science Inc., Fort Washington, PA 19034, USA

Dr. David A. Schwartz

Perinatal Pathology Consulting, Atlanta, GA, USA

Dr. Gary Kobinger

1. Centre de Recherche en Infectiologie, Université Laval, Québec, QC, Canada
2. Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada
3. Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

Deadline for manuscript submissions

closed (31 August 2018)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/14377

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2024).